The goal of this Observational Prospective Multi-center Study is to observe the acute and long-term safety and performance outcomes after spatiotemporal dispersion-based AF/AT ablation utilizing the Volta Medical AI software in "real-life" clinical practice, without any imposed clinical workflow. Moreover, this study will allow to collect medico-economic data related to the tailored ablation strategy guided by the Volta Medical AI software.
All patients enrolled are treated for atrial fibrillation/tachycardia via a catheter ablation procedure using Volta Medical AI software during the mapping phase to identify areas of interest specific to the patient. The ablation approach is free and chosen by the operator according to standard practice. Intraoperative and postoperative follow-up will be performed as in routine clinical practice during AF ablation procedures: hospitalization for ablation procedure and standard postoperative quarterly visits (at 3 months, at 6 months and/or 9 months as per the study investigator's Standard Of Care) then annual visits up to 24 months post-ablation. Adverse Events, recurrences of atrial arrhythmia and AF related symptoms (EHRA score) are collected from the patient's enrollment until the patient's study termination. A quality-of-life questionnaire related to general health (EQ-5D-3L) is collected during the preoperative visit and at least during annual follow-up visits. The patient's study-termination corresponds to the last annual visit at 24 months post-ablation index.
Study Type
OBSERVATIONAL
Enrollment
186
All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient. The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are: * 3D mapping of the atria and location of areas of interest; * Catheter ablation at the operator\'s discretion.
Hôpital Saint-Joseph
Marseille, France
Hôpital Privé Jacques Cartier
Massy, France
Polyclinique Saint George
Nice, France
Centre Cardiologique du Nord
Saint-Denis, France
Clinique Rhéna
Strasbourg, France
Clinique Pasteur
Toulouse, France
German Heart Center Munich
München, Germany
Freedom from clinically significant AF or atrial arrhythmia recurrence, after one or multiple ablation procedures, with or without antiarrhythmic drugs, stratified by type of clinical workflow.
Time frame: [24 months]
VX1/Volta AF-Xplorer/Volta AF-Xplorer II-related Incident rate during ablation procedure.
Time frame: [24months]
VX1/Volta AF-Xplorer/Volta AF-Xplorer II-related Adverse Event rate.
Time frame: [24months]
Progression of Quality-Of-Life score ("EQ-5D-3L") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
Time frame: Preoperative; [24months]
Progression of the AF related symptom score ("EHRA") during the study (at inclusion, at quarterly visits, at 12 months and at 24 months).
Time frame: Preoperative; [24months]
Hospitalization rate during the post-ablation follow-up period.
Time frame: [24months]
Serious Adverse Event rate during the post-ablation follow-up period.
Time frame: [24months]
Average number of ablation procedures per patient up to 24 months follow-up.
Time frame: [24months]
Average number of cardioversions per patient up to 24 months follow-up
Time frame: [24months]
Progression of patient proportion under antiarrhythmic drugs and/or anticoagulant treatments during the study.
Time frame: [24months]
Health economics analysis including QALY metric.
Time frame: [24months]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.